Accession Number:

AD1095683

Title:

Testing a Novel Therapy to Treat NF1-Related Skeletal Defects

Descriptive Note:

Technical Report,30 Sep 2018,29 Sep 2019

Corporate Author:

UTSW Medical Center Dallas United States

Personal Author(s):

Report Date:

2019-10-01

Pagination or Media Count:

8.0

Abstract:

Osteolectin was recently identified as a protein secreted from bone mesenchymal stem cells MSC that promotes osteoblast differentiation when injected subcutaneously into mice. As NF1 patient fracture pseudarthroses are caused, at least in part, by defects in osteoblast differentiation of MSCs, the goal of this study is to evaluate whether osteolectin rescues osteoblast differentiation of patient pseudarthrosis-derived MSCs. Second as subcutaneously-injected Osteolectin improves skeletal development in mice, we are also testing whether osteolectin therapy may rescue skeletal development in an established mouse model of NF1 bone disease. If successful, this study may identify Osteolectin as a potentially novel therapy for NF1-associated skeletal disease.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE